Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: Implications for identifying hyperandrogenaemia

L. W. Cho, E. S. Kilpatrick, V. Jayagopal, M. J. Diver, Stephen Atkin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: Hyperandrogenaemia is one of the three Rotterdam consensus diagnostic criteria for polycystic ovarian syndrome (PCOS) and may be measured by estimation of total testosterone, free androgen index (FAI) or bioavailable testosterone (BioT). The aim of this study was to compare the biological variability of total testosterone with that of the biological variability of both the FAI and BioT, to determine the least variable measurement for clinical practice. Design: Comparative study. Patients: Blood samples were collected after an overnight fast at 4-day intervals on 10 consecutive occasions from 12 PCOS patients and 11 weight- and age-matched control women. Measurements: Duplicate samples of stored serum were analysed for total testosterone, SHBG and BioT in a single batch. Results: The PCOS group had a significantly higher median BioT, FAI and total testosterone than controls. In both the PCOS and control groups, the intraindividual variance was small and similar for BioT and FAI. There was no significant difference between the within-subject biological coefficient of variation (CVI) for BioT, FAI and total testosterone. The maximum and minimum critical differences were +58% and -37% for BioT and +70% and -40% for FAI, respectively. Conclusion: FAI appears to be the better diagnostic marker to distinguish hyperandrogenism in patients with PCOS, but once diagnosis has been made, all three methods should be equally good in monitoring further changes in the androgen status.

Original languageEnglish
Pages (from-to)390-394
Number of pages5
JournalClinical Endocrinology
Volume68
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Androgens
Testosterone
Hyperandrogenism

ASJC Scopus subject areas

  • Endocrinology

Cite this

Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome : Implications for identifying hyperandrogenaemia. / Cho, L. W.; Kilpatrick, E. S.; Jayagopal, V.; Diver, M. J.; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 68, No. 3, 03.2008, p. 390-394.

Research output: Contribution to journalArticle

@article{3a3c85e6ba3244eba30be41484abc7f6,
title = "Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: Implications for identifying hyperandrogenaemia",
abstract = "Objective: Hyperandrogenaemia is one of the three Rotterdam consensus diagnostic criteria for polycystic ovarian syndrome (PCOS) and may be measured by estimation of total testosterone, free androgen index (FAI) or bioavailable testosterone (BioT). The aim of this study was to compare the biological variability of total testosterone with that of the biological variability of both the FAI and BioT, to determine the least variable measurement for clinical practice. Design: Comparative study. Patients: Blood samples were collected after an overnight fast at 4-day intervals on 10 consecutive occasions from 12 PCOS patients and 11 weight- and age-matched control women. Measurements: Duplicate samples of stored serum were analysed for total testosterone, SHBG and BioT in a single batch. Results: The PCOS group had a significantly higher median BioT, FAI and total testosterone than controls. In both the PCOS and control groups, the intraindividual variance was small and similar for BioT and FAI. There was no significant difference between the within-subject biological coefficient of variation (CVI) for BioT, FAI and total testosterone. The maximum and minimum critical differences were +58{\%} and -37{\%} for BioT and +70{\%} and -40{\%} for FAI, respectively. Conclusion: FAI appears to be the better diagnostic marker to distinguish hyperandrogenism in patients with PCOS, but once diagnosis has been made, all three methods should be equally good in monitoring further changes in the androgen status.",
author = "Cho, {L. W.} and Kilpatrick, {E. S.} and V. Jayagopal and Diver, {M. J.} and Stephen Atkin",
year = "2008",
month = "3",
doi = "10.1111/j.1365-2265.2007.03053.x",
language = "English",
volume = "68",
pages = "390--394",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome

T2 - Implications for identifying hyperandrogenaemia

AU - Cho, L. W.

AU - Kilpatrick, E. S.

AU - Jayagopal, V.

AU - Diver, M. J.

AU - Atkin, Stephen

PY - 2008/3

Y1 - 2008/3

N2 - Objective: Hyperandrogenaemia is one of the three Rotterdam consensus diagnostic criteria for polycystic ovarian syndrome (PCOS) and may be measured by estimation of total testosterone, free androgen index (FAI) or bioavailable testosterone (BioT). The aim of this study was to compare the biological variability of total testosterone with that of the biological variability of both the FAI and BioT, to determine the least variable measurement for clinical practice. Design: Comparative study. Patients: Blood samples were collected after an overnight fast at 4-day intervals on 10 consecutive occasions from 12 PCOS patients and 11 weight- and age-matched control women. Measurements: Duplicate samples of stored serum were analysed for total testosterone, SHBG and BioT in a single batch. Results: The PCOS group had a significantly higher median BioT, FAI and total testosterone than controls. In both the PCOS and control groups, the intraindividual variance was small and similar for BioT and FAI. There was no significant difference between the within-subject biological coefficient of variation (CVI) for BioT, FAI and total testosterone. The maximum and minimum critical differences were +58% and -37% for BioT and +70% and -40% for FAI, respectively. Conclusion: FAI appears to be the better diagnostic marker to distinguish hyperandrogenism in patients with PCOS, but once diagnosis has been made, all three methods should be equally good in monitoring further changes in the androgen status.

AB - Objective: Hyperandrogenaemia is one of the three Rotterdam consensus diagnostic criteria for polycystic ovarian syndrome (PCOS) and may be measured by estimation of total testosterone, free androgen index (FAI) or bioavailable testosterone (BioT). The aim of this study was to compare the biological variability of total testosterone with that of the biological variability of both the FAI and BioT, to determine the least variable measurement for clinical practice. Design: Comparative study. Patients: Blood samples were collected after an overnight fast at 4-day intervals on 10 consecutive occasions from 12 PCOS patients and 11 weight- and age-matched control women. Measurements: Duplicate samples of stored serum were analysed for total testosterone, SHBG and BioT in a single batch. Results: The PCOS group had a significantly higher median BioT, FAI and total testosterone than controls. In both the PCOS and control groups, the intraindividual variance was small and similar for BioT and FAI. There was no significant difference between the within-subject biological coefficient of variation (CVI) for BioT, FAI and total testosterone. The maximum and minimum critical differences were +58% and -37% for BioT and +70% and -40% for FAI, respectively. Conclusion: FAI appears to be the better diagnostic marker to distinguish hyperandrogenism in patients with PCOS, but once diagnosis has been made, all three methods should be equally good in monitoring further changes in the androgen status.

UR - http://www.scopus.com/inward/record.url?scp=39149102526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149102526&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2007.03053.x

DO - 10.1111/j.1365-2265.2007.03053.x

M3 - Article

C2 - 17888022

AN - SCOPUS:39149102526

VL - 68

SP - 390

EP - 394

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -